Objective To remind health care professionals to be more alert to the risk of severe constipation associated with dapagliflozin and to provide reference for safe use of this drug.Methods The clinical process of treating a patient who developed severe constipation after taking dapagliflozin tablets was analyzed.Based on related literature,the possible mechanisms and treatment regimens of severe constipation caused by sodium-glucose cotransporter 2 inhibitors(SGLT-2i)were studied.Results One patient developed severe constipation after taking dapagliflozin.After discontinuation of the drug,the patient's constipation improved.However,upon re-administration of dapagliflozin,the patient relapsed into constipation.Immediately after drug withdrawal and treatment with laxatives to moisten the intestines,the patient's conditions improved.The causal relationship of adverse reactions was defined as"definite",so the severe constipation of this patient was considered to have been caused by dapagliflozin.Conclusion Constipation poses a significant threat to patients'quality of life and may potentially precipitate cardiovascular events.Therefore,it is imperative to enhance clinicians'awareness and pharmacological surveillance regarding the adverse effects of constipation associated with dapagliflozin and SGLT-2i.
NETL
NSTL
万方数据
